

In the claims:

Kindly amend claims numbered 43 and 51 as follows:

C 2 43. (Twice Amended) A method for the treatment of conditions mediated by nuclear receptors, the method comprising administering to a subject in need thereof an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

C 3 51. (Amended) The pharmaceutical composition of claim 36, wherein the compound is in a unit dosage form in the amount of between 0.1 to about 50 mg.

Kindly add new claim number 55 as follows:

C 4 55. (New) A method for the treatment of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

RESPONSE

The Examiner has noted that the oath/declaration filed concurrently with the application and preliminary amendment did not specifically refer to the preliminary amendment as required by 37 C.F.R. §1.63(b)(2). Applicant regrets this oversight, is in the process of securing the inventor's signatures on the new oath/declaration, and will forward the signed document to the Patent Office upon its receipt from the inventors.

The Examiner has rejected claims numbered 1, 2, 7, 16, 18, 23, 24, 26-33, 36, 43, 44, and 50-54 under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to